ストックスクリーナーアプリを入手
2.85
9.20%
0.24
アフターアワーズ：
2.80
-0.05
-1.75%
Newcelx Ltd (NCEL) 最新ニュース
Positive Signs As Multiple Insiders Buy NewcelX Stock - Simply Wall Street
NewcelX (Nasdaq: NCEL) outlines $25M share deal with Alpha - Stock Titan
NewcelX (NASDAQ: NCEL) warns on cash as diabetes trial plans advance - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com
NewcelX Ltd (NCEL) Slides 2.87% to $3.38, Approaches Key Support at $3.21Mean Reversion Trade - siam.in
NewcelX (NCEL) Latest: Moves 3.18% Down to $3.26 in the Latest Session; the Near-Term Reference Band Stretches From $3.10 to $3.42 in Latest TradingPut Dominated - vinanet.vn
NewcelX (NCEL) Latest: Moves 3.18% Down to $3.26 in the Latest Session; the Near-Term Reference Band Stretches From $3.10 to $3.42 in Latest TradingHot Stock Picks - dars.gov.et
NewcelX Ltd (NCEL) Shareholders to Sell 694,000 Shares Amid Unpr - GuruFocus
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Wyckoff Upthrust - vinanet.vn
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Bullish Sentiment - dars.gov.et
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Composite Profile - dars.gov.et
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX (NCEL) Slides 6.2% to $3.34, Testing Key Support Near $3.17Diagonal Spread Trade - vinanet.vn
NewcelX Lines Up $1.4 Million Private Placement to Advance Type 1 Diabetes Program - theglobeandmail.com
NewcelX Ltd. (NCEL) Rises 3.83% to $3.49, Testing Key Resistance at $3.66Death Cross - vinanet.vn
Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - Moomoo
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative
NewcelX Prices $1.4 Million Premium Equity Financing to Advance Type 1 Diabetes Cell Therapy - TipRanks
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Post-Earnings Moves - dars.gov.et
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Retail Volume - vinanet.vn
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Income Statement - TradingKey
NewcelX Ord Shs (NCEL) Balance Sheet - TradingKey
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Cash Flow - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NewcelX (NCEL) Secures Patent for Innovative Technology - GuruFocus
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio - The Manila Times
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineRip Sell Trade - dars.gov.et
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineAAII Bearish - dars.gov.et
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Nigeria
Laidlaw Initiates NewcelX(NCEL.US) With Buy Rating, Announces Target Price $23 - Moomoo
NCEL Initiated Coverage by Laidlaw & Co. -- Price Target Announced at $23 - GuruFocus
Laidlaw initiates NewcelX stock with buy rating on diabetes therapy - Investing.com
NLSP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com South Africa
NewcelX Strengthens Diabetes Push With Appointment of Leading Transplant Pioneer Camillo Ricordi - TipRanks
NewcelX appoints diabetes researcher Ricordi to advisory board - Investing.com
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - The Manila Times
NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development. - Pluang
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Canada
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com UK
1.35%
大文字化:
|
ボリューム (24 時間):